Amatoxin Conjugates Plasma Stability via Linker Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody-drug conjugates (ADCs) face challenges in delivering potent RNA polymerase inhibitors to cancer cells while maintaining stability in plasma, which affects the therapeutic window and safety, with limited stability of amatoxin conjugates prior to internalization.
Innovation Solution
Development of novel cytotoxic cyclic peptides, analogs of alpha-amanitin and beta-amanitin, for use in antibody-drug conjugates, specifically modifying the 7′ position of the indole ring with a CH2SH moiety and linker components to facilitate attachment to antibodies, enhancing stability and targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amatoxin conjugates are used as ADC payloads to inhibit RNA polymerase, then cytotoxic activity against cancer cells is improved, but stability in plasma prior to internalization deteriorates
Solution Approach 1:
A plasma-stable linker is introduced as an intermediary component between the amatoxin payload and the antibody. This linker maintains the integrity of the conjugate in plasma circulation while allowing controlled release of the cytotoxic amatoxin payload upon internalization into target cells, thus resolving the contradiction between plasma stability and cytotoxic activity.
Solution Approach 2:
The ADC is segmented into distinct functional components: a plasma-stable linker segment, an antigen-binding antibody segment, and a cytotoxic amatoxin payload segment. This segmentation allows each component to perform its specific function optimally - the linker provides plasma stability while the payload delivers cytotoxic activity upon release.
2Productivity
If amatoxin conjugates are delivered to cancer cells, then inhibition of cell proliferation is improved, but therapeutic window and safety deteriorate due to limited stability
Solution Approach 1:
The plasma-stable linker acts as a protective intermediary that prevents premature release of the toxic amatoxin payload in circulation, thereby improving safety and expanding the therapeutic window. The linker ensures the payload is delivered intact to target cells before release, reducing off-target effects.
Solution Approach 2:
The chemical parameters of the linker are specifically designed to be stable under plasma conditions (pH 7.4, presence of proteases) but become labile under intracellular conditions (endosomal/lysosomal pH, enzymatic environment). This parameter change enables selective payload release at the target site, improving both efficacy and safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel cytotoxic cyclic peptides improve the stability and targeted delivery of RNA polymerase inhibitors to cancer cells, effectively inhibiting cell proliferation and treating cancer with enhanced safety and therapeutic efficacy.
Implementation Method 1
modifying the 7′ position of the indole ring with a CH2SH moiety and linker components to facilitate attachment to antibodies
Implementation Method 2
Amatoxins are potent and selective inhibitors of RNA polymerase II, a vital enzyme in the synthesis of messenger RNA (mRNA), microRNA, and small nuclear RNA (snRNA). By inhibiting the synthesis of mRNA, Amatoxins thereby stop cell metabolism by inhibiting transcription and protein biosynthesis
Data Source
AI summary
The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (A), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.e Antibody Drug Conjugates), pharmaceutical compositions comprising such cyclic peptides immunoconjugates, compositions comprising such cyclic peptides immunoconjugates with a therapeutic co-agent and methods of treatment using such cyclic peptides immunoconjugates: